RE: Clarity On Debt Funding31 Jul 2023 19:34
There's no trading update yet, so whether my 2023 forecast is on track is impossible to conclusively say right now. But I previously said "maybe the night is not really so black nor so full or terrors when you actually chew over the numbers." So how do I feel about that comment ahead of any trading update?
1. Right now we have a supportive investor who can open doors in Asia. That's a positive from the get go. The dilutive effect today would be £1.46m @ 1.8p/share = 19.4% - the maximum dilutive effect (of 43%) diminishes as the SP rises. If the share price goes to 3.6p then the dilution is below 10%. The 2nd tranche of the convertible may not be needed although kicks in in 3 months.
2. We also know from the last numbers they have "invested in growth" so we are definitely seeing growth based on the Twitter updates aren't we?
3. Hidden in the 2022 numbers was growth of ~70% in the USA which **far** exceeded WHI's 2022 forecast (of 12%). The lacklustre performance in China/Singapore was to be expected - although the WHI deal will be a key support for that strategy/expansion in 2023. I'm reading about tourism numbers exploding in SE Asia. EI is well placed to serve those markets bouncing back.
4. Stock of £1.7m. US bottling and run down of stock levels will mean a reduction of circa £0.6m working capital is possible in 2023.
5. I said that funding req'ts would be circa £2.5m so was quite close on that. The lower funding suggests my estimates on sales & margin were too low. An increase in Margin due to US Bottling said (by WHIreland) to be worth 12% improvement to margin (although strangely they foresaw only a 5% increase to margin in 2023). Using 30% margin and extrapolating growth I forecast at the start of 2023 a 2023 Revenue of £6m and GP of £1.8m. Net of Costs a 2023 loss of £2.2m.
6. Roughly, on a cash burn of £0.2m a month, EI now has 6-9 months runway taking it to Q2 2024.
7. But if EI can get Asia growth of 70% (like they achieved in the USA) now supported by WHI, as well as continued US growth supported by its local bottling partner, along with margin increases to 32% through bottling, logistic savings, price rises, while volume increases more quickly through that extra investment in "admin" (aka sales&mkg) reaching £9m sales and a GP of £3.4m seems feasible. Combined with streamlining inventory and invoice finance and you can see operational cashflow and EBITDA breakeven in H1 2024 and much improved for 2023 as a whole.
My original 2023 Forecast for EISB:
Revenue £6.4m
COS £4m
GP £2.4m
Admin £3.7m
EBITDA -£1.3m
My new 2023 Forecast for EISB:
Revenue £9m
COS £5.6m
GP £3.4m
Admin £3.9m* (I've added £0.2k for interest accruing)
EBITDA -£0.5m
If we see WHI convert some or all of their loan later this year, this will be an extremely strong buy signal. Equally, the pressure is on the BOD to perform. If they fail, WHI takes Anthony Burt's 18.8% holding.
GLA